Dr
Jonathan
Atkinson

Partner & Patent Attorney

Leeds Office

Telephone. +44(0) 113 233 0100
Mobile. +44(0) 776 665 6290
Email. [email protected]

Experience

Jonathan's practice involves providing commercially-focussed advice on patent origination, patent strategy and portfolio management, licensing and due diligence, prosecuting and defending European patent oppositions, and conducting patent litigation in the UK and Europe.

His practice draws in this variety of experience and extends to a wide range of chemical and pharmaceutical subject matter. Jonathan's practice in the pharmaceutical area has covered both contentious and non-contentious issues and he has provided external consultancy services to a number of large pharmaceutical companies over the last 20 years.

His practice involves providing commercially focused advice to C-suite business leaders, R&D groups, and public institutions on all aspects of patent strategy and portfolio management. This includes obtaining and defending patent rights, providing opinions on freedom to operate where third party intellectual property rights exist, conducting due diligence to support corporate acquisition and licensing deals, challenging third party patent rights and pan-European pharmaceutical litigation.

Jonathan has worked on a number of high profile pharmaceutical matters including working as part of the patent procurement team for Viagra™; prosecution and litigation surrounding Augmentin™, Ritalin™ and Fosrenol™; opposition/appeal work on Zithromax™, Perindopril and Sovaldi™ and due diligence work to support acquisitions (eg New River Pharmaceuticals and Renovo, and IPO's (eg Redx and NuCana plc), and private equity investment funding (eg OriBiotech).

In the non-pharmaceutical area, he has been responsible for filing all of the foundation patents for graphene on behalf of Manchester University's two Nobel Prize winners Geim and Novoselov.

Jonathan's clients include large and small companies, universities and government organisations.

Specialisms

  • Catalysis
  • Energy
  • Material science
  • Pharmaceutical technologies
  • Physical chemistry
  • Printing technologies

Industries

  • CleanTech icon CleanTech
  • Healthcare icon Healthcare
  • Medical devices icon Medical devices
  • Pharmaceuticals icon Pharmaceuticals

Services

  • Due diligence
  • In-house legal support
  • IP litigation
  • Patent oppositions & appeals
  • Patent term extensions & SPCs
  • Patents
  • Portfolio management
  • Searching & competitor monitoring
  • Strategy
  • Transactional IP & commercial support

Qualifications

Patent Attorney

European


BA

Chemistry (Oxon)

MA

Chemistry (Oxon)

OTHER

D.Phil. (Oxon)

POSTGRADUATE DIPLOMA OR CERTIFICATE

Cert in IP Law Queen Mary, London

POSTGRADUATE DIPLOMA OR CERTIFICATE

C. Chem, FRSC

Publications

IAM Patent 1000 2019

View publication online

Related News

Managing Intellectual Property IP Stars & Firm Rankings 2021

Managing Intellectual Property IP Stars 2021, comprising the highly recommended IP professionals, has now been published. HGF is delighted to have 14 European attorneys listed. IP STARS is the leading …

Read article

Medical technology most patented subject matter at EPO in 2020

Pharmaceutical and biotechnology patent applications also make top 10 most patented. Recent statistics published by the EPO show that a total of 14,295 European patent applications were filed in 2020 …

Read article

The EPO ‘How To’ guide for antibody applications in Europe

The 2021 EPO Guidelines provide much needed guidance on how to protect antibodies in Europe. Biological drugs including therapeutic antibodies have become increasingly important to the pharmaceutical industry. The European …

Read article

Personalised drug patenting in Europe

Opportunities for additional pharmaceutical product patent protection in Europe, based on the use of a drug to treat a patient exhibiting a biomarker indicative of drug response. Recent years have …

Read article

The Internet of Medical Things

Exploring the growth of patents for connected medical devices, and how best to protect them. The Internet of Things (IoT) is expected to change our lives by creating a connected …

Read article

Covid-19 vaccine patent waivers

To waive, or not to waive, that is the question. The earliest identified date of a patient presenting with symptoms of a “novel coronavirus” in Wuhan, China is reported to …

Read article

G1/21 hearing at the EPO

Follow this page for the updates from G1/21 hearing at the EPO on 28th May 2021. HGF Partners Dr Chris Moore and Douglas Drysdale will be reporting all the key …

Read article
Event - 9th June 2021

Webinar: Developing effective patent strategies for personalised medical devices in Europe and the US

HGF in Europe and Knobbe Martens in the US are holding a joint webinar on 9th June. In this webinar we will explore considerations for implementing an effective strategy to …

Event details

Let's talk

If you would like to discuss how HGF could help you, contact one of our IP specialists.